RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

  • Feature ArticlesFeature Articles

    Drug shortages in Germany ‒ A critical appraisal

    The article discusses drug shortages in Germany the root causes of production problems with active pharmaceutical ingredients and drug product manufacturers. The authors offer analysis from a medium-sized generic drug manufacturer’s perspective. They offer a variety of reasons, all of which point to a “broken marketplace.” The article concludes with a discussion of mitigation activities and in an epilog address the current COVID-19 pandemic, warning that drugs and active i...
  • Feature ArticlesFeature Articles

    Electronic platforms for submission of clinical trial information

    This article provides guidance for use of the European electronic platforms for retrieving and submitting information about clinical trials and compares them with other similar regional electronic databases, such as the US Food and Drug Administration’s MyStudies mobile app and Switzerland’s national platform, swissethics. The authors present an overview of some of the main international portals, available and under development, and provide an analysis of their specific as...
  • Feature ArticlesFeature Articles

    Impact of the Revised EU Clinical Trial Regulation

    Clinical Trial Regulation EU No 536/2014 will come into effect in 2018. This article reports on aspects of the revised regulation and evaluates its potential impact on clinical trials conducted to assess medicinal products for human use. It discusses changes impacting the critical role of the Ethics Committees in the approval process for clinical trials as well as the planned, centralized data reporting channel, referred to as "the portal." While revisions to the regulat...
  • Feature ArticlesFeature Articles

    CFDI's Global Drug Inspection Trend Study Offers Regulatory Updates and Opinions

    To help keep regulatory professionals up-to-date on current thinking by global regulatory agencies, the Chinese Center of Food and Drug Inspection (CFDI) released a new electronic journal covering hot topics and developments in international drug manufacturing inspections. This article summarizes the key points including regulatory thinking and opinions from global regulatory authorities and organizations; timely updates on regulations, guidance, regulatory measures and ...
  • Feature ArticlesFeature Articles

    CFDA Publishes Four Draft Guidances on Inspections of Generic Drug Development

    This article provides the details of four draft guidances published on 21 December 2016 by the China Food and Drug Administration (CFDA) regarding on-site inspection of generic drugs, including how CFDA will be evaluating their quality and efficacy and possible inspection outcomes and the responsibilities of 31 local province level FDA inspection teams in China. 1 The first guidance published by the CFDA covers on-site inspections of generic drug development establi...
  • Feature ArticlesFeature Articles

    Draft CFDA Guidance on Drug Data Management Practices

    The China Food and Drug Administration (CFDA) has recently issued a new draft guidance document on data integrity, covering the entire data lifecycle from R&D to commercial production and distribution. This article is a translation of the summary of the draft guidance. On 10 October 2016, CFDA issued draft guidance of drug data management practices for public comment. 1 Its purpose as detailed in Chapter I is the regulating the management of relevant data during th...
  • Feature ArticlesFeature Articles

    Registration Procedures for Medicinal Products in China

    This article provides a high-level introduction to the Chinese regulatory framework, including requirements for marketing approval of imported drugs. An increasing number of pharmaceutical companies based outside China are interested in marketing their products in China as evidenced by the increasing number of clinical trial and marketing applications submitted by foreign companies. Obtaining marketing authorization approval equal to an Import Drug License (IDL) approv...
  • Feature ArticlesFeature Articles

    Competency Expectations for the Regulatory Professional: A Changing Paradigm

    Regulatory professionals working for pharmaceutical service providers possess different competency levels, mainly depending on their previous experience. Recent market studies 1 reveal new trends in regulatory outsourcing and complete business processes are being transferred to service providers as strategic partners, necessitating changes in competencies expected from regulatory professionals. As a result of these changes, new competency paradigms will be based ...
  • Feature ArticlesFeature Articles

    Outsourcing: Not My Problem?

    The author attended a conference and workshop on outsourcing 2–3 December 2014 in Berlin. This article summarizes the topics discussed and the issues identified during the event, sponsored by the Parenteral Drug Association (PDA), which was well attended by industry representatives (contract givers), suppliers (contract acceptors) and consultants. It was clear from the discussions during and after the conference sessions the vast majority of outsourcing decisions an...
  • Feature ArticlesFeature Articles

    Pharmaceutical Outsourcing: A Korean Perspective

    The pharmaceutical industry in Asia has been growing rapidly for many years. However, while the pharmaceutical industries in China, Singapore and India are well known, much less is written about South Korea, perhaps because pharmaceutical products make up only 0.4% of its total exports. This article looks at the possible causes for this from a regulatory and compliance perspective, while taking into account the political agenda and other influencing factors. Speci...
  • Feature ArticlesFeature Articles

    China's Regulatory Procedure and Inspection System

    China is a mysterious and interesting country for the regulatory professional. It is of interest because of its enormous market potential (nearly a fifth of the world’s population lives in the People’s Republic of China) and the fact that China is one of the most important manufacturers of active pharmaceutical ingredients (APIs) for the EU and US. China exported 1.2 million tons of APIs to the EU and 0.6 million tons to the US in 2013. China is somewhat mysterious becau...
  • Feature ArticlesFeature Articles

    Looking to the Future in Regulatory Affairs

    Predicting the future is, of course, like gazing into a crystal ball; therefore, the reader is warned that the following is based in part on indicators from industry and the regulators, but mostly on personal considerations and expectations, and discussions with peers in the regulatory community. There are many strands to consider when looking to the future in regulatory affairs. The first strand is the regulations and how these are likely to be impacted by a globalized ...